Mailing Address
45 Rockefeller Plaza, 20th Floor, New York, NY 10111
212-268-1002
Washington DC Office
1101 14th Street NW, Suite 850, Washington, DC 20005
866-399-6262 (Toll Free) | 202-331-2292 (Fax)
Make an online donation today.
Mail your contributions to the address below:
Ovarian Cancer Research Alliance
Post Office Box 32141
New York, NY 10087-2141
Tax ID #13-3806788
We’re here for you! Our Patient Support team is available to take your calls Monday – Friday. Call 212-268-1002 and if no one is available when you call, someone will get back to you within 24 hours.
For all press inquiries, please contact:
Amanita Duga-Carroll
ADC Strategic Communications, Inc.
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued
OCRA’s Annual Advocacy Day Draws Survivors and Caregivers from Across the Country More than 120 gynecologic cancer survivors, caregivers, researchers and supporters from nearly forty states filled the halls of the U.S. Capitol on Tuesday, March 17—dressed in teal, the color of ovarian cancer awareness—as Ovarian Cancer Research Alliance (OCRA) held its annual Spring Advocacy Day. The … Continued
April is a full month at OCRA, with several new programs joining our ongoing lineup of workshops, educational sessions, and community events. Whether you’re looking for practical guidance, clinical information, or simply a chance to connect and create, there’s something here for you. New and Expanded Programs Advanced Care Planning Workshop Series April 6, 13, … Continued
Get email updates about research news, action alerts, and ways to join the fight.
